Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
NCT05488431 is a phase 2 interventional trial sponsored by Priscilla Hsue, MD. As of 21 Nov 2026, it is recruiting participants. It studies Bempedoic acid in Atherosclerosis, Cardiovascular Diseases and 2 more conditions. The registry lists an enrollment of 121 participants at 3 sites in 1 country. The registry lists a start date of 1 Mar 2023 and a primary completion date of 1 Mar 2028. 4 of its registered investigators have a FindMyKOL profile.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT05488431 |
| Status | Recruiting |
| Phase | Phase 2 |
| Study type | Interventional trial |
| Lead sponsor | Priscilla Hsue, MD |
| Enrollment | 121 |
| Registered sites | 3 |
| Countries | 1 |
| Conditions | Atherosclerosis, Cardiovascular Diseases, Dyslipidemias and HIV Infections |
| Drugs | Bempedoic acid |
| Start | 1 Mar 2023 |
| Primary completion | 1 Mar 2028 |
| Study completion | 1 Mar 2028 |
| Last update posted | 17 Dec 2025 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Ucla Center for Clinical Aids Research and Education (care)
Los Angeles
Judith Currier, MDPriscilla Hsue, MD →Recruiting - San Francisco General Hospital
San Francisco
Adam Spivak, MDAhmed Tawakol, MDBorek Foldyna, MDJohn Kornak, MDMichael Lu, MDMiguel Pampaloni, MDPriscilla Hsue, MD →Steven Deeks, MDYoojin Lee, MDRecruiting
- Ut Health Houston
Houston
Jordan Lake, MDRecruiting
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT05488431
Each answer restates registry values shown on this page.
What is NCT05488431?
NCT05488431 is a phase 2 interventional trial sponsored by Priscilla Hsue, MD. It studies Bempedoic acid in Atherosclerosis, Cardiovascular Diseases and 2 more conditions.
Is NCT05488431 recruiting?
As of 21 Nov 2026, it is recruiting participants. 3 of its 3 sites list their own status as recruiting.
Who leads NCT05488431?
The registry names Priscilla Hsue, MD (principal investigator, University of California, Los Angeles) as the overall official.
Where does NCT05488431 run?
The registry lists 3 sites in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT05488431 study?
The registered drug and biological interventions are Bempedoic acid.
When is NCT05488431 expected to complete?
The registry lists a primary completion date of 1 Mar 2028 and a study completion date of 1 Mar 2028. The sponsor last updated the record on 17 Dec 2025.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.